Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Jia-yuan Liu
Higher Programmed Cell Death 1 Ligand 1 (PD-L1) mRNA Level in Clear Cell Renal Cell Carcinomas Is Associated With a Favorable Outcome Due to the Active Immune Responses in Tumor Tissues
Oncotarget
Oncology
Related publications
Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1)
American Journal of Surgical Pathology
Anatomy
Forensic Medicine
Pathology
Surgery
Programmed Death Ligand 1 in Non-Clear Cell Renal Cell Carcinoma and Correlation With Tumor Microenvironment and Prognostic Factors
Medical Journal of Islamic World Academy of Sciences
The Prognostic Role of Immune Checkpoint Markers Programmed Cell Death Protein 1 (PD-1) and Programmed Death Ligand 1 (PD-L1) in a Large, Multicenter Prostate Cancer Cohort
Oncotarget
Oncology
PD-1 Receptor (PDCD1; PD-1; CD279); Programmed Cell Death 1 Ligand 1 (CD274 Molecule; PD-L1; B7-H1)
Science-Business eXchange
Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation
Cancer immunology research
Cancer Research
Immunology
Endothelial Programmed Death-1 Ligand 1 (PD-L1) Regulates CD8+ T-Cell-Mediated Injury in the Heart
Circulation
Cardiovascular Medicine
Physiology
Cardiology
Poor Outcome With Anti-Programmed Death-Ligand 1 (PD-L1) Antibody Due to Poor Pharmacokinetic Properties in PD-1/PD-L1 Blockade-Sensitive Mouse Models
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
Diverse Cutaneous Adverse Eruptions Caused by Anti-Programmed Cell Death-1 (PD-1) and Anti-Programmed Cell Death Ligand-1 (PD-L1) Immunotherapies: Clinical Features and Management
Therapeutic Advances in Medical Oncology
Oncology
Programmed Death-1 Ligand 2-Mediated Regulation of the PD-L1 to PD-1 Axis Is Essential for Establishing CD4 + T Cell Immunity
Immunity
Infectious Diseases
Allergy
Immunology
